Cassidy Henegar, PhD, MSPH

Director
ViiV Healthcare

Disclosure(s): ViiV Healthcare: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-225) Polypharmacy, Drug-Drug Interactions, and Risk of Hospitalization among Veterans with HIV Taking 2-, 3-, and 4-Drug Antiretroviral Therapy Regimens
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-345) Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-376) The US REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET